DESCRIPTION (provided by applicant): Production of a human apyrase protein as an antithrombotic agent is proposed. Thrombotic vascular occlusion due to abnormal platelet aggregation can lead to many diseases, including ischemic stroke, myocardial infarction, and restenosis after angioplasty or… More

DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a novel antithrombotic drug that is safer and more effective than current therapies. Phase I funding for this project supported the successful development of a novel expression system to facilitate efficient production… More

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet a ctivation and aggregation with modest… More

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to reduce ischemia/reperfusion injury which occurs in10-20% of lung transplant recipients as the consequence of unavoidable processes of procurement, preservation and restoring blood flow. This clinical… More

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an… More

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered… More

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vascular integrity and inhibits platelet activation and agg regation without increasing bleeding risk.… More

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. Using a protein informatics approach, we have successfully engineered a human… More

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet a ctivation and aggregation with modest… More

DESCRIPTION (provided by applicant): Acute myocardial infarction is the leading cause of death in most industrialized nations. The estimated annual incidence in the US is 865,000 events, with ST-segment elevation myocardial infarction (STEMI, severe AMI)comprising an estimated 500,000 events per… More

DESCRIPTION (provided by applicant): The saphenous vein is the most commonly used graft for coronary artery bypass and peripheral bypass surgery, but has poor patency. 15-20% grafts fail in the first month and approximately 25% in the first year. Early vein graft occlusion is typically due to… More